TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00679653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 10 mg, capsules, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 10 mg, capsules, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 10 mg, capsules, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 15 mg, capsules, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 15 mg, capsules, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 15 mg, capsules, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil/trandolapril
Description: 2 wk Run-in phase, antihypertensive therapy only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol/HCT
Description: 2 wk Run-in phase, antihypertensive therapy only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: felodipine/ramipril
Description: 2 wk Run-in phase, antihypertensive therapy only
Study: NCT02441166

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mastocytosis diagnosis
Description: Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
Study: NCT02695641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25mg bevacizumab
Description: Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.50mg bevacizumab
Description: Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
Study: NCT00427336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 by vein daily over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 by vein daily over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: 3.75 mg/kg by vein daily over 4 hours
Study: NCT03278951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Person Group
Study: NCT01746680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus with Methotrexate
Description: Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
Study: NCT00454389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epi-Rad90™ Ophthalmic System
Description: A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
Study: NCT03717948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR Exercise
Description: Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR Exercise
Description: Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTL Exercise
Description: Participants will exercise on a recumbent bike placed on flat ground (CTL).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTL Exercise
Description: Participants will exercise on a recumbent bike placed on flat ground (CTL).
Study: NCT03072277

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosa Hexaenoic Acid (DHA)
Description: 400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
Study: NCT03539341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH-Thailand parenting programme
Description: Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control (care as usual)
Description: The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
Study: NCT04136665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Adapted program
Description: 6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
Study: NCT03603028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Mixed Reality Gaming for Chronic Low Back Pain
Study: NCT04826211

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
Study: NCT01037244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT03680404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Phenylephrine)
Description: This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine + Apocynin
Description: This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine + Allopurinol
Description: This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine + Tempol
Description: This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
Study: NCT02851082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training program
Description: Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases.
Study: NCT03086213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: anaesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: anaesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfentanyl
Description: anaesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfentanyl
Description: anaesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: anaesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: anaesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local anaesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anaesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: local anaesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anaesthetics
Study: NCT03355170

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lansoprazole/Domperidone
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Active comparator
Study: NCT04557605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive cycling exercise test to exhaustion
Description: Progressive step cycling exercise test to exhaustion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive cycling exercise test to exhaustion
Description: Progressive step cycling exercise test to exhaustion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive cycling exercise test to exhaustion
Description: Progressive step cycling exercise test to exhaustion
Study: NCT01844245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
Study: NCT01562457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
Study: NCT01874860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline capsule, 100 mg, taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream
Description: Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Applied to exposed skin areas at least 30 minutes before going outdoors each morning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Applied to exposed skin areas at least 30 minutes before going outdoors each morning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Recommended for daily use if rash returns (Topical cream)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medrol-dose pack (Steroid)
Description: Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
Study: NCT01038063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Study: NCT00395460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: 1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist
Description: 0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
Study: NCT01006928

Intervention type: OTHER
Intervention: Questionaire
Description: Questionaire to mothers
Study: NCT03604523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation by Balloon
Description: Esophageal dilation by balloon device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation by Semi-rigid Savary
Description: Esophageal dilation by semi-rigid savary device
Study: NCT01136772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol decanoate
Description: haloperidol decanoate injections, 25-200 mg once a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: Paliperidone palmitate injections, 39 mg - 234 mg once a month
Study: NCT01100034

Intervention type: DRUG
Intervention: Etanercept
Description: Expected duration of 24 weeks as one course
Study: NCT02931825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder letter
Description: The letter will consist in several parts:~* Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~* Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~* Request information if they've done their follow-up or if we have incorrect information~* Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer
Study: NCT04572087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral training and verum stimulation
Description: Cognitive control training and verum tDCS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral training and sham stimulation
Description: Cognitive control training and sham tDCS
Study: NCT03760705

Intervention type: OTHER
Intervention: Data Collection
Description: 1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data.
Study: NCT04631419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flapless laser corticotomy
Description: The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flapless laser corticotomy
Description: The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canine retraction
Description: canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canine retraction
Description: canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canine retraction
Description: canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canine retraction
Description: canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
Study: NCT03760705

Intervention type: OTHER
Intervention: Data Collection
Description: 1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data.

Intervention type: OTHER
Intervention: Data Collection
Description: 1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data.
Study: NCT00452088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP 3 Long Synthetic Peptide
Description: Lyophilized vaccine given at 15 or 30 microgrammes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP 3 Long Synthetic Peptide
Description: Lyophilized vaccine given at 15 or 30 microgrammes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis vaccine adjuvanted in Aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B control vaccince
Description: Hepatitis B vaccine adjuvanted in Aluminium hydroxide
Study: NCT03134157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral drug and vaginal placebo
Description: prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral drug and oral placebo
Description: prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal placebo+ oral placebo
Description: prescription of Vaginal placebo + oral placebo every day for 3 months.
Study: NCT02354443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProHema-CB Transplant
Description: ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
Study: NCT00141726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
Study: NCT03123809

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gastric Electrical Stimulation (GES) System
Description: Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Electrical Stimulation (GES) System
Description: Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
Study: NCT02681133

Intervention type: OTHER
Intervention: Epidemiological study Survey
Study: NCT00829582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETI-204, Anthim
Description: single intravenous infusion of 120, 240 or 360 mg of ETI-204

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: single intravenous infusion
Study: NCT03046784

Intervention type: OTHER
Intervention: haemodynamic evaluation
Description: continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
Study: NCT01164124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
Description: The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: routine feedings